Deal History
About us
The Company
Team
Offices
Globalscope
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Services
Corporate Finance
Debt Advisory
Equity Research
Growth Equity Financing
IPO Strategy & Preparation
Industries
Business Services
Consumer
Industrial Technology
Healthcare
Software
Energy
Research
Equity Research
Macro and Markets
Career
Events
Insights
News
Company News
Deal News
In the Media
Newsletter
Contact
Newsletter
INT
DA
DE
FR
SV
US
Main menu button
Team
Deals
Contact
Team
Deals
Contact
News
All
Company News
Deal News
Equity Research
Events
In the Media
Insights
Macro and Markets
All
Abera Bioscience
All for One Group
ALM Equity
Alzecure Pharma
Angler Gaming
Arctic Minerals
Biosergen
Candles Scandinavia
Carlsquare
CDON
CellaVision
CSAM Health Group
Elicera Therapeutics
Enrad
Frequentis
Future Gaming
GHP Specialty Care
Hanza
Herantis Pharma
Immunovia
InCoax
Kancera
KlaraBo
Lohilo Foods
Lokotech
Medclair Invest
Midsummer
Modus Therapeutics
Moninvent
Nischer Properties
Nosa Plugs
Observit
Orion Corporation
Risk Intelligence
SBB i Norden
Spotlight Group
Svenska Aerogel
Teneo AI
Thinc Collective
Viva Wine Group
White Pearl Technology Group
Zinzino
All
02 Mar 2026
Equity Research ALM Equity Q4 2025: Higher profit with a thousand housing starts per year
Equity Research
ALM Equity
01 Mar 2026
Equity research Enrad, Q4 2025: A Sweden push to accelerate growth
Equity Research
Enrad
27 Feb 2026
Equity research Enrad, Q4 2025: Soft sales but order pipeline intact
Equity Research
Enrad
27 Feb 2026
Equity research Zinzino Q4 2025: Healthy scalability
Equity Research
Zinzino
26 Feb 2026
Equity Research ALM Equity, Q4 2025: Increased cash and improved prospects
Equity Research
ALM Equity
25 Feb 2026
Equity research Immunovia Q4 2025: Targeting Medicare sub-mission by mid-2026
Equity Research
Immunovia
25 Feb 2026
Equity research Zinzino Q4 2024: First impression - Margins significantly above our expectations
Equity Research
Zinzino
24 Feb 2026
Equity research Immunovia Q4 2025: First impression - Modest Q4 sales, targeting Medicare submission by mid-2026
Equity Research
Immunovia
22 Feb 2026
Equity research Enrad, Q4 2025: A profit for the quarter may be on the cards
Equity Research
Enrad
20 Feb 2026
Equity research Viva Wine Group Q4 2025: Delta profit surprise raises spirits
Equity Research
Viva Wine Group
20 Feb 2026
Equity research Angler Gaming, Q4 2025: A year defined by margin improvement
Equity Research
Angler Gaming
19 Feb 2026
Equity research Viva Wine Group Q4 2025: First impression - Better than expected as Delta surprises
Equity Research
CDON
19 Feb 2026
Equity research Angler Gaming, Q4 2025: Another quarter with margins expansion
Company News
Angler Gaming
18 Feb 2026
Equity research White Pearl Technology Group: A growth and profitability engine at a discount
Equity Research
White Pearl Technology Group
16 Feb 2026
Equity Research KlaraBo, Q4 2025: Dividends and share buybacks support the share price
Equity Research
KlaraBo
16 Feb 2026
Equity research CDON, Q4 2025: Macro tailwinds and initiatives support outlook
Equity Research
CDON
13 Feb 2026
Equity research CDON Q4 2025: First impression - Good growth and encouraging 2027 target
Equity Research
CDON
13 Feb 2026
Equity Research KlaraBo, Q4 2025: Dividend on the shares was the best news
Equity Research
KlaraBo
12 Feb 2026
Equity research White Pearl Technology Group, Q4 2025: Margin miss clouded an otherwise strong growth quarter
Equity Research
White Pearl Technology Group
12 Feb 2026
Equity research Candles Scandinavia Q4 2025: Sustained double-digit growth
Equity Research
Candles Scandinavia
1
2
3
…
63